A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes

被引：0
|
作者：
Kosei Kimura
Mitsuhiko Iwamoto
Satoru Tanaka
Daigo Yamamoto
Katsuhide Yoshidome
Hiroyuki Ogura
Risa Terasawa
Nobuki Matsunami
Yuko Takahashi
Toshikatsu Nitta
Takashi Morimoto
Hiroya Fujioka
Kanako Kawaguchi
Kazuhisa Uchiyama
机构：
[1] Osaka Medical College Hospital,Department of Breast and Endocrine Surgery
[2] National Hospital Organization Osaka Minami Medical Center,Department of Breast Surgery
[3] Kansai Medical University Medical Center,Department of Breast Surgery
[4] Osaka Police Hospital,Department of Breast and Endocrine Surgery
[5] Hamamatsu University School of Medicine,Department of Breast Surgery
[6] Osaka Rosai Hospital,Department of Breast Surgery
[7] Hirakata City Hospital,Department of Breast and Endocrine Surgery
[8] Medico Shunju Shiroyama Hospital Breast Center,Division of Surgery
[9] Yao Municipal Hospital,Department of Breast Surgery
来源：
Cancer Chemotherapy and Pharmacology | 2018年 / 81卷
关键词：
Eribulin; Metastatic breast cancer; First or second-line; Objective response rate; QOL;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：923 / 933
页数：10
相关论文
共 50 条
  • [21] All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial
    Tubiana-Mathieu, N.
    Bougnoux, P.
    Becquart, D.
    Chan, A.
    Conte, P-F
    Majois, F.
    Espie, M.
    Morand, M.
    Vaissiere, N.
    Villanova, G.
    BRITISH JOURNAL OF CANCER, 2009, 101 (02) : 232 - 237
  • [22] All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial
    N Tubiana-Mathieu
    P Bougnoux
    D Becquart
    A Chan
    P-F Conte
    F Majois
    M Espie
    M Morand
    N Vaissiere
    G Villanova
    British Journal of Cancer, 2009, 101 : 232 - 237
  • [23] Trastuzumab and first-line taxane chemotherapy in metastatic breast cancer patients with a HER2-negative tumor and HER2-positive circulating tumor cells: a phase II trial
    Noortje Verschoor
    Manouk K. Bos
    Ingeborg E. de Kruijff
    Mai N. Van
    Jaco Kraan
    Jan C. Drooger
    Johanna M. Zuetenhorst
    Saskia M. Wilting
    Stefan Sleijfer
    Agnes Jager
    John W. M. Martens
    Breast Cancer Research and Treatment, 2024, 205 : 87 - 95
  • [24] Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine
    Pivot, Xavier
    Im, Seock Ah
    Guo, Matthew
    Marme, Frederik
    BREAST CANCER, 2018, 25 (03) : 370 - 374
  • [25] A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer
    Metzger Filho, Otto
    Giobbie-Hurder, Anita
    Lin, Nancy U.
    Faggen, Meredith
    Come, Steven
    Openshaw, Thomas
    Constantine, Michael
    Walsh, Jeanna
    Freedman, Rachel A.
    Schneider, Bryan
    Burstein, Harold J.
    Mayer, Erica L.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 185 (01) : 135 - 144
  • [26] A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer
    Otto Metzger Filho
    Anita Giobbie-Hurder
    Nancy U. Lin
    Meredith Faggen
    Steven Come
    Thomas Openshaw
    Michael Constantine
    Jeanna Walsh
    Rachel A. Freedman
    Bryan Schneider
    Harold J. Burstein
    Erica L. Mayer
    Breast Cancer Research and Treatment, 2021, 185 : 135 - 144
  • [27] Trastuzumab and first-line taxane chemotherapy in metastatic breast cancer patients with a HER2-negative tumor and HER2-positive circulating tumor cells: a phase II trial
    Verschoor, Noortje
    Bos, Manouk K.
    de Kruijff, Ingeborg E.
    Van, Mai N.
    Kraan, Jaco
    Drooger, Jan C.
    Zuetenhorst, Johanna M.
    Wilting, Saskia M.
    Sleijfer, Stefan
    Jager, Agnes
    Martens, John W. M.
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 205 (01) : 87 - 95
  • [28] Use of Eribulin mesylate as second-line therapy in elderly patients with HER/2 negative metastatic breast cancer (MBC): efficacy, tolerability and Quality of Life
    De Luca, R.
    Alu, M.
    Genova, G.
    Grassadonia, A.
    Cicero, G.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (24) : 12727 - 12734
  • [29] VicTORia: a randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line chemotherapy in advanced HER2-negative breast cancer
    Decker, Thomas
    Marschner, Norbert
    Muendlein, Axel
    Welt, Anja
    Hagen, Volker
    Rauh, Jaqueline
    Schroeder, Helge
    Jaehnig, Peter
    Potthoff, Karin
    Lerchenmueller, Christian
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 176 (03) : 637 - 647
  • [30] VicTORia: a randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line chemotherapy in advanced HER2-negative breast cancer
    Thomas Decker
    Norbert Marschner
    Axel Muendlein
    Anja Welt
    Volker Hagen
    Jaqueline Rauh
    Helge Schröder
    Peter Jaehnig
    Karin Potthoff
    Christian Lerchenmüller
    Breast Cancer Research and Treatment, 2019, 176 : 637 - 647
12345